2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer ...Middle East

SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...

Read More Details
Finally We wish PressBee provided you with enough information of ( 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer )

Also on site :

• US launches new probe into India’s Adani over Iran trade – WSJ
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Tuesday, June 3
• Joe Jonas Reflects on Infamous ‘South Park’ Episode: ‘I Was the Only Brother That Loved It’